Pharmacokinetic basis for dosing high‐dose methotrexate in infants and young children with malignant brain tumours

Abstract

By aggressively following institutional clinical guidelines, HDMTX-related toxicities were low, and using covariates from the population pharmacokinetic model enabled the calculation of a rational dosage for this patient population for future clinical trials.